ViroMed
-
ViroMed receives approval for Phase II trial in the US for diabetic peripheral neuropathy
ViroMed announced that VM202-DPN, the company's proprietary DNA medicine for treatment of diabetic peripheral neuropathy, has received approval from the US FDA for a Phase II clinical trial.
ViroMed | 04 January 2012
-
ViroMed Receives Approval of Phase II Trial for Peripheral Artery Disease Drug
ViroMed has announced that VM202-PAD, a Deoxyribonucleic Acid (DNA) medicine for the treatment of Peripheral Artery Disease (PAD), has received approval from the US Food and Drug Administration (FDA) for a Phase II clinical trial. The trial will be p…
ViroMed | 24 July 2009
-
ViroMed Completes Trial for Cardiovascular Disease Treatment
ViroMed has announced that the final injections for patients enrolled in a Phase I clinical trial in China for VM202, the company’s proprietary DNA medicine for various types of cardiovascular disease (CVD), have been completed. The clinical tri…
ViroMed | 11 June 2009
-
ViroMed Receives US FDA Approval for Clinical Trial
ViroMed has announced that it has received an approval from the US Food and Drug Administration (FDA) for a Phase I/II trial for VM202-CAD. The heart disease medicine is being jointly developed with Biologics Delivery Systems Group, Cordis Corporatio…
ViroMed | 17 March 2009
-
ViroMed Receives Approval for Diabetic Neuropathy Phase I/II Trial
ViroMed has received approval from the US Food and Drug Administration (FDA) to start clinical trials for diabetic neuropathy, a major complication of diabetes mellitus. The Phase I/II clinical trial will take place at various medical centers, inc…
ViroMed | 06 March 2009
-
Cobrabio and ViroMed to form a joint venture
Cobra Biomanufacturing says it has extended its manufacturing agreement and intends to form a joint venture with ViroMed Co. Ltd (South Korea). The extended collaboration includes a long term research, development and technical consultancy agreem…
ViroMed | 30 July 2008
-
Cobrabio announces manufacturing agreement with ViroMed for VM206RY
Cobra Biomanufacturing Plc, the international manufacturer of biopharmaceuticals, says it has signed an agreement with ViroMed Co., Ltd. in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast, ovarian, pancreatic…
ViroMed | 11 June 2008
